Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors

Annals of Oncology

Volumn 16, Issue 8, 2005, Pages 1391-1397

  Holden, S N ^a   Eckhardt, S G ^a   Basser, R ^b   de Boer, R ^b   Rischin, D ^b   Green, M ^b   Rosenthal, M A ^b   Wheeler, C ^c   Barge, A ^c   Hurwitz, H I ^d  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b Cancer Trials Australia   (Australia)

^c ASTRAZENECA   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anti angiogenesis; Dose escalation; Pharmacokinetics; Tolerability; ZD6474

Indexed keywords

ALANINE AMINOTRANSFERASE; VANDETANIB;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLITIS; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLICULITIS; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; HYPOPHOSPHATEMIA; INCIDENCE; INTESTINE ISCHEMIA; INTESTINE OBSTRUCTION; KIDNEY CANCER; LIVER CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; MULTICENTER STUDY; NAUSEA; PHASE 1 CLINICAL TRIAL; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSTATE CANCER; QT PROLONGATION; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 23844544081     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi247     Document Type: Article

References (30)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-257.
2. Ellis LM, Liu W, Fan F et al. Role of angiogenesis inhibitors in cancer treatment. Oncology 2001; 15: 39-46.
3. Madhusudan S, Harris AL. Drug inhibition of angiogenesis. Curr Opin Pharmacol 2002; 2: 403-414.
4. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002; 20: 3906-3927.
5. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674.
6. Keck PJ, Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312.
7. Lamoreaux WJ, Fitzgerald ME, Reiner A et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29-42.
8. Pepper MS, Montesano R, Mandriota SJ et al. Angiogenesis: A paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996; 49: 138-162.
9. Benjamin LE, Golijanin D, Itin A et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-165.
10. Carmeliet P, Lampugnani MG, Moons L et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999; 98: 147-157.
11. Bates DO, Heald RI, Curry FE, Williams B. Vascular endothelial growth factor increases Rana vascular permeability and compliance by different signalling pathways. J Physiol 2001; 533: 263-272.
12. Dvorak HF, Detmar M, Claffey KP et al. Vascular permeability factor/ vascular endothelial growth factor: An important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol 1995; 107: 233-235.
13. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
14. Hennequin LF, Stokes ES, Thomas AP et al. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002; 45: 1300-1312.
15. Ciardiello F, Caputo R, Damiano V et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9: 1546-1556.
16. Wedge SR, Ogilvie DJ, Dukes M et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645-4655.
17. Ciardiello F, Bianco R, Caputo R et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004; 10: 784-793.
18. Bruns CJ, Kohl G, Guba M et al. Anti-angiogenic and anti-tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Proc Am Assoc Cancer Res 2003; 44: 604.
19. Therasse P. Response Evaluation Criteria in Solid Tumours. Eur J Cancer 2002; 38: 1817-1823.
20. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-370.
21. Beal SL, Sheiner LB. Estimating population kinetics. Crit Rev Biomed Eng 1982; 8: 195-222.
22. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992; 20: 511-528.
23. Lockhart AC, Braun RD, Yu D et al. Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res 2003; 9: 586-593.
24. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-434.
25. Drevs J, Mross K, Medinger M et al. Phase I dose-escalation and pharmacokinetic (PK) study of the VEGF inhibitor PTK787/ZK222584 (PTK/ ZK) in patients with liver metastases. Proc Am Soc Clin Oncol 2003; Abst 1142.
26. Raymond E, Faivre S, Vera K et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003; Abst 769.
27. Veronese ML, Flaherty KT, Townsend R et al. Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension. Proc Am Soc Clin Oncol 2004; Abstr 2035.
28. Bruns CJ, Solorzano CC, Harbison MT et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60: 2926-2935.
29. Solorzano CC, Baker CH, Tsan R et al. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma. Clin Cancer Res 2001; 7: 2563-2572.
30. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. J Am Med Assoc 2003; 290: 2149-2158.